Table S1. Univariate analyses of predictors of the primary and secondary endpoint at one year in the PCI/CABG group.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Primary endpoint | | Secondary endpoint | |
|  | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Demographics | | | | |
| Age, per 10 yrs | 1.00 (0.97-1.03) | 0.97 | 1.01 (0.99-1.03) | 0.39 |
| Male | 1.05 (0.47-2.33) | 0.91 | 1.07 (0.63-1.80) | 0.81 |
| BMI, per 1 kg/m2 | 0.93 (0.86-1.01) | 0.09 | 0.97 (0.93-1.02) | 0.29 |
| Heart failure | | | | |
| LVEF, per 5% | 0.96 (0.92-0.99) | 0.01 | 0.98 (0.96-1.00) | 0.06 |
| HFREF | 1.28 (0.38-4.25) | 0.69 | 1.27 (0.63-2.54) | 0.51 |
| Previous HF hospitalization | 1.27 (0.60-2.66) | 0.53 | 1.03 (0.65-1.65) | 0.90 |
| Medical history | | | | |
| Hypertension | 0.89 (0.42-1.87) | 0.76 | 0.60 (0.38-0.96) | 0.03 |
| Myocardial infarction | 0.48 (0.15-1.57) | 0.23 | 0.60 (0.26-1.37) | 0.22 |
| Atrial fibrillation | 2.83 (1.41-5.68) | 0.004 | 1.89 (1.23-2.92) | 0.004 |
| Peripheral artery disease | 0.76 (0.27-2.16) | 0.61 | 1.20 (0.68-2.13) | 0.53 |
| Diabetes | 1.14 (0.57-2.26) | 0.71 | 1.66 (1.08-2.56) | 0.02 |
| COPD | 0.49 (0.12-2.05) | 0.33 | 1.03 (0.51-2.05) | 0.94 |
| Stroke | 0.21 (0.03-1.56) | 0.13 | 1.02 (0.51-2.04) | 0.95 |
| Current smoking | 0.63 (0.31-1.29) | 0.20 | 0.90 (0.57-1.42) | 0.64 |
| Clinical status at admission | | | | |
| Cardiogenic shock | - | 1.00 | - | 1.00 |
| NYHA class | 2.12 (1.25-3.58) | 0.01 | 1.58 (1.15-2.16) | 0.004 |
| SBP, per 10 mmHg | 0.99 (0.97-0.999) | 0.04 | 0.99 (0.98-1.00) | 0.07 |
| Heart rate,  per 10 b.p.m. | 1.01 (1.00-1.03) | 0.04 | 1.01 (0.997-1.02) | 0.16 |
| VF or VT as a cause of admission | 1.48 (0.45-4.85) | 0.52 | 1.2 (0.53-2.79) | 0.64 |
| ACS as a cause of admission | 0.56 (0.25-1.24) | 0.15 | 0.88 (0.54-1.44) | 0.61 |
| AF as a cause of admission | 2.41 (1.05-5.56) | 0.04 | 2.34 (1.33-4.10) | 0.003 |
| Laboratory findings at admission | | | | |
| Serum sodium | 0.88 (0.80-0.96) | 0.01 | 0.91 (0.86-0.96) | 0.001 |
| Serum potassium, per 0.5 mmol/l | 2.01 (1.04-3.87) | 0.04 | 0.99 (0.65-1.52) | 0.97 |
| Serum creatinine,  per 1 mg/dl | 1.63 (1.15-2.30) | 0.01 | 1.39 (1.06-1.81) | 0.02 |
| Hemoglobin,  per 1 g/dl | 0.97 (0.81-1.15) | 0.72 | 0.95 (0.84-1.07) | 0.41 |
| Major management during index hospitalization, clinical status and laboratory finding at discharge | | | | |
| PCI/CABG during hospitalization | 0.65 (0.25-1.70) | 0.38 | 1.09 (0.64-1.86) | 0.75 |
| ICD implantation during hospitalization | 0.99 (0.35-2.81) | 0.98 | 0.79 (0.41-1.54) | 0.50 |
| Heart rate,  per 10 b.p.m. | 1.02 (0.99-1.05) | 0.14 | 1.00 (0.98-1.02) | 0.96 |
| Pharmacotherapy at hospital discharge | | | | |
| Diuretics | 2.65 (0.63-11.06) | 0.18 | 1.51 (0.76-3.03) | 0.24 |
| Aldosterone antagonist | 1.11 (0.53-2.32) | 0.79 | 1.45 (0.89-2.35) | 0.13 |
| ACE-I | 0.58 (0.28-1.19) | 0.13 | 0.63 (0.39-0.996) | 0.048 |
| ARB | 0.29 (0.04-2.13) | 0.23 | 0.66 (0.29-1.52) | 0.33 |
| β-blocker | 0.81 (0.25-2.66) | 0.73 | 0.79 (0.38-1.64) | 0.53 |
| Statin | 0.68 (0.29-1.56) | 0.36 | 0.68 (0.40-1.14) | 0.14 |
| Anticoagulants | 1.90 (0.96-3.75) | 0.07 | 1.62 (1.05-2.50) | 0.03 |
| Antiplateletes | 0.39 (0.18-0.84) | 0.02 | 0.60 (0.36-1.01) | 0.06 |

ACE-I, angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFREF, heart failure with reduced ejection fraction; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; VF, ventricular fibrillation; VT, ventricular tachycardia; yrs, years

In case of questionable validity of the model fit, “–“ statement was used.

A *P* value of <0.05 is considered statistically significant.

Table S2. Univariate analyses of predictors of the primary and secondary endpoint at one year in the non-PCI/CABG group.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Primary endpoint | | Secondary endpoint | |
|  | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Demographics | | | | |
| Age, per 10 yrs | 1.06 (1.03-1.09) | <0.0001 | 1.01 (0.99-1.02) | 0.24 |
| Male | 0.63 (0.37-1.06) | 0.08 | 0.87 (0.61-1.24) | 0.44 |
| BMI, per 1 kg/m2 | 0.97 (0.92-1.03) | 0.37 | 1.02 (0.98-1.05) | 0.35 |
| Heart failure | | | | |
| LVEF, per 5% | 0.99 (0.98-1.02) | 0.72 | 0.99 (0.98-1.01) | 0.24 |
| HFREF | 1.22 (0.63-2.36) | 0.55 | 1.43 (0.92-2.22) | 0.11 |
| Previous HF hospitalization | 0.78 (0.46-1.31) | 0.34 | 1.35 (0.94-1.94) | 0.11 |
| Medical history | | | | |
| Hypertension | 1.51 (0.85-2.70) | 0.16 | 0.90 (0.62-1.30) | 0.58 |
| Myocardial infarction | 1.85 (1.09-3.13) | 0.02 | 1.20 (0.84-1.72) | 0.32 |
| Atrial fibrillation | 1.07 (0.63-1.82) | 0.81 | 1.09 (0.76-1.57) | 0.65 |
| Peripheral artery disease | 1.75 (0.70-4.38) | 0.23 | 0.91 (0.40-2.08) | 0.83 |
| Diabetes | 1.85 (1.09-3.14) | 0.02 | 1.14 (0.78-1.66) | 0.51 |
| COPD | 1.09 (0.52-2.31) | 0.82 | 1.01 (0.60-1.70) | 0.98 |
| Stroke | 1.21 (0.52-2.82) | 0.66 | 1.29 (0.74-2.26) | 0.37 |
| Current smoking | 1.06 (0.62-1.82) | 0.82 | 0.99 (0.68-1.42) | 0.94 |
| Clinical status at admission | | | | |
| Cardiogenic shock | 2.38 (0.86-6.59) | 0.10 | 2.08 (0.97-4.47) | 0.06 |
| NYHA class | 1.84 (1.26-2.69) | 0.002 | 1.57 (1.22-2.02) | 0.001 |
| SBP, per 10 mmHg | 0.99 (0.98-1.00) | 0.049 | 0.99 (0.98-0.99) | 0.001 |
| Heart rate,  per 10 b.p.m. | 1.01 (1.00-1.02) | 0.01 | 1.00 (0.99-1.01) | 0.23 |
| VF or VT as a cause of admission | 0.93 (0.23-3.82) | 0.92 | 0.47 (0.12-1.90) | 0.29 |
| ACS as a cause of admission | 1.97 (1.16-3.35) | 0.01 | 1.18 (0.80-1.73) | 0.41 |
| AF as a cause of admission | 1.24 (0.64-2.40) | 0.52 | 1.27 (0.80-2.04) | 0.32 |
| Laboratory findings at admission | | | | |
| Serum sodium | 0.90 (0.86-0.93) | <0.0001 | 0.94 (0.91-0.98) | 0.004 |
| Serum potassium, per 0.5 mmol/l | 0.92 (0.60-1.41) | 0.71 | 0.87 (0.65-1.17) | 0.37 |
| Serum creatinine,  per 1 mg/dl | 1.00 (0.93-1.08) | 0.995 | 1.20 (0.98-1.46) | 0.09 |
| Hemoglobin,  per 1 g/dl | 0.84 (0.74-0.95) | 0.01 | 0.86 (0.78-0.94) | 0.001 |
| Major management during index hospitalization, clinical status and laboratory finding at discharge | | | | |
| PCI/CABG during hospitalization | 1.38 (0.63-3.04) | 0.43 | 0.82 (0.43-1.57) | 0.55 |
| ICD implantation during hospitalization | 0.62 (0.09-4.50) | 0.64 | 0.68 (0.18-2.74) | 0.59 |
| Heart rate,  per 10 b.p.m. | 1.03 (1.02-1.04) | <0.0001 | 1.01 (1.00-1.02) | 0.02 |
| Pharmacotherapy at hospital discharge | | | | |
| Diuretics | 2.32 (0.93-5.82) | 0.07 | 1.61 (0.93-2.76) | 0.09 |
| Aldosterone antagonist | 1.14 (0.66-1.99) | 0.64 | 1.20 (0.82-1.76) | 0.35 |
| ACE-I | 0.62 (0.36-1.08) | 0.09 | 0.95 (0.64-1.40) | 0.78 |
| ARB | 0.60 (0.19-1.90) | 0.38 | 0.81 (0.42-1.54) | 0.52 |
| β-blocker | 0.50 (0.27-0.94) | 0.03 | 0.77 (0.48-1.23) | 0.27 |
| Statin | 0.98 (0.57-1.69) | 0.95 | 0.86 (0.60-1.23) | 0.41 |
| Anticoagulants | 1.08 (0.63-1.84) | 0.79 | 1.34 (0.93-1.91) | 0.11 |
| Antiplateletes | 1.23 (0.70-2.16) | 0.47 | 0.76 (0.53-1.10) | 0.14 |

ACE-I, angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFREF, heart failure with reduced ejection fraction; HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; VF, ventricular fibrillation; VT, ventricular tachycardia; yrs, years

A *P* value of <0.05 is considered statistically significant.